SAN DIEGO, Aug. 26, 2025 /PRNewswire/ — Debut, the biotech beauty leader, has secured $20M in investment to accelerate the expansion of its proprietary, AI-based ingredient discovery platform to advance skin longevity innovation and scale its formulation business in the US and Asia.
The funding will propel the discovery of next-generation ingredients that target the 14 hallmarks of aging and empower Debut’s global beauty partners to innovate with peak-performing biotech ingredients and formulations married to novel claims. It will also enable beauty brands at all stages of growth to outsource their formulation innovation in record time, at scale and without the heavy upfront R&D expense associated with biotech.
“Debut is laser-focused on staying at the forefront of skincare innovation and bringing cutting-edge biotech to every beauty brand with the highest-performing and most differentiated ingredients. This funding will enhance our ability to screen upward of 50 billion ingredients to explore the 99.999 percent of unknown molecules that can optimize skin health and make skin longevity a reality,” said Joshua Britton, PhD, Founder and CEO of Debut.
The predictive capabilities of Debut’s proprietary, in-house skin health datasets recently surpassed publicly available datasets, achieving 99 percent data consistency compared to 85 percent in public datasets. “This means we can predict better ingredients, faster, with our best-in-class models that we have invested in over several years. We are excited to go after novel chemical entities (NCEs), as opposed to chasing existing ingredients in nature, to pioneer skin health innovation and support the growth of beauty brands,” said Britton.
Debut’s funding raise comes at a time marked by increased investor caution. The company is poised to enter the Asian market which is driven by advanced formulations and high-performance skincare. “AI combined with an understanding of skin biology enables the creation of custom formulation solutions for different geographies that has previously not been possible,” said Britton. Debut’s expansion into Asia will begin in Singapore where the company will be partnering with leading brands to create custom ingredients and formulations for longevity skincare.
The most recent fundraising round was supported by Fine Structure Ventures, EDBI, Wealthberry, BOLD (the venture fund of L’Oréal), GS Futures, Sandbox Industries and Material Impact, among others.
Debut
The leader in biotech beauty
Debut is building the future of beauty with cutting-edge AI and biotechnology, creating high-performing, innovative ingredients and formulations that propel the industry forward. The company specializes in scientifically-discovered, clinically-proven and inherently sustainable ingredients that provide maximum efficacy. Named one of the TIME100 Most Innovative Companies 2025, Debut is redefining the beauty industry’s standards, centering on performance, potency and purity.
SOURCE Debut Biotechnology
